44 Antibody

What is the beta Amyloid (1-42) Polyclonal Antibody (44-344)?

The beta Amyloid (1-42) Polyclonal Antibody (catalog number 44-344) is a research antibody that specifically recognizes the human Abeta42 peptide. This antibody shows no significant cross-reactivity to Abeta40 and previous lots have demonstrated no cross-reactivity to Abeta43. While not explicitly tested, cross-reactivity against Abeta42 from multiple species (mouse, rat, pig, cow, sheep, dog, rabbit, frog, and polar bear) is expected due to 100% sequence homology across these species .

This antibody has demonstrated utility in various experimental applications including ELISA, dot blots, radioimmunoassay (RIA), and related assay formats. It specifically targets the 42-amino acid variant of beta amyloid, which is a major component of the extracellular plaques found in Alzheimer's disease brain tissue .

What are CD44 variant antibodies and how do they differ from each other?

CD44 variant antibodies are monoclonal antibodies specifically engineered to target different splice variants of the CD44 protein. These variants arise from alternative splicing of the CD44 gene, resulting in isoforms with variable exon insertions. Researchers have developed a comprehensive panel of antibodies against specific CD44 variants:

• C44Mab-5: An anti-pan-CD44 mAb that recognizes epitopes within constant exon 2- and 5-encoded sequences

• C44Mab-6: Specifically targets CD44 variant 3 (CD44v3)

• C44Mab-108: Specifically targets CD44 variant 4 (CD44v4)

• C44Mab-3: Specifically targets CD44 variant 5 (CD44v5)

• C44Mab-9: Specifically targets CD44 variant 6 (CD44v6)

• C44Mab-34: Specifically targets CD44 variant 7/8 (CD44v7/8)

• C44Mab-1: Specifically targets CD44 variant 9 (CD44v9)

• C44Mab-18: Specifically targets CD44 variant 10 (CD44v10)

These antibodies differ in their epitope specificity, allowing researchers to distinguish between different CD44 splice variants in experimental settings. This distinction is crucial as different variants play unique roles in cancer progression and stemness .

How is the specificity of 44-series antibodies validated?

For beta amyloid antibodies (44-344 and 44-348), specificity validation typically involves:

• Cross-reactivity testing against related peptides (e.g., testing 44-344 against Abeta40 and Abeta43)

• Confirmation of reactivity using Western blotting with purified peptides

• Mass spectrometry validation to confirm target identity

For CD44 variant antibodies, validation procedures include:

• Flow cytometry screening against cells overexpressing specific CD44 variants versus control cells

• ELISA screening for reactivity against purified CD44 ectodomain

• Western blot analysis to confirm molecular weight and specificity

• Immunohistochemical validation using appropriate positive and negative tissue controls

These validation approaches ensure that the antibodies specifically recognize their intended targets with minimal cross-reactivity to related proteins.

What protocols are recommended for using beta Amyloid antibodies in immunohistochemistry?

When using beta amyloid antibodies like 44-344 and 44-348 for immunohistochemistry, researchers should follow these methodological steps:

• Sample preparation: Fix tissue sections appropriately (typically formalin-fixed, paraffin-embedded) and section at 5-10 μm thickness .

• Antigen retrieval: Treat sections with 90% formic acid for 30 minutes to enhance amyloid beta immunoreactivity .

• Endogenous peroxidase blocking: Incubate sections with 0.2% hydrogen peroxide in methanol .

• Nonspecific binding blocking: Treat sections with 10% fetal bovine serum in phosphate buffer solution (PBS) for 30 minutes .

• Primary antibody incubation: Dilute antibodies in 10% fetal bovine serum in PBS and incubate with sections overnight at 4°C .

• Secondary antibody application: Incubate with biotinylated sheep anti-mouse IgG or biotinylated donkey anti-rabbit IgG antibody (1:200 dilution) for 30 minutes .

• Signal development: Treat with extravidin peroxidase conjugate (1:200) for 1 hour and visualize with diaminobenzidine (0.5 mg/ml with 1.5% hydrogen peroxide in PBS) .

• Counterstaining: Lightly counterstain with cresyl violet for tissue context .

This protocol enhances detection sensitivity while maintaining specificity for beta amyloid species.

How should researchers apply CD44v4 antibodies in experimental workflows?

The anti-CD44v4 monoclonal antibody (C44Mab-108) has been validated for multiple experimental applications. For optimal results, researchers should consider the following methodological approaches:

• Flow cytometry:

  • Use 1 μg of C44Mab-108 per 1×10^6 cells

  • Incubate for 30 minutes at 4°C

  • Wash cells with 1% BSA in PBS

  • Apply appropriate fluorophore-conjugated secondary antibody

• Western blotting:

  • Load 10-20 μg of total protein per lane

  • Transfer to PVDF membrane

  • Block with 5% skim milk

  • Apply C44Mab-108 at 10 μg/mL concentration

  • Use peroxidase-conjugated anti-mouse immunoglobulins (1:1000 dilution)

  • Develop with chemiluminescence detection system

• Immunohistochemistry:

  • Use formalin-fixed paraffin-embedded (FFPE) tissues

  • Perform antigen retrieval using citrate buffer (pH 6.0)

  • Apply C44Mab-108 at 1-5 μg/mL concentration

  • Proceed with appropriate detection system

  • C44Mab-108 has demonstrated effectiveness in staining oral squamous carcinoma tissues

The binding affinity (KD) of C44Mab-108 for CD44v3-10 has been determined to be 3.4 × 10^-7 M, which provides sufficient sensitivity for most research applications .

What methods can be used to quantify Aβ peptides when using 44-series antibodies?

Several quantitative methods have been validated for use with beta amyloid antibodies (44-344 and 44-348):

• Western blotting: A highly sensitive method capable of detecting sub-femtomol quantities of Aβ. The protocol involves:

  • Homogenization of brain samples in formic acid

  • Neutralization of extract aliquots

  • PAGE separation in tris-tricine 16% gels

  • Transfer and immunoblotting with appropriate antibodies

  • Quantification against standard curves

• Immunopurification followed by mass spectrometry:

  • Immuno-adsorption to antibody-coupled matrix (e.g., Aminolink)

  • Elution with 2.5% trifluoroacetic acid in 50% acetonitrile

  • Analysis by mass spectrometry to determine specific Aβ isoforms

  • This method recovers approximately 50% of total Aβ peptides

• ELISA:

  • Coat plates with capture antibody

  • Incubate with samples and standards

  • Detect with enzyme-conjugated secondary antibody

  • Develop with appropriate substrate (e.g., TMB)

  • Measure absorbance at 450 nm versus 620 nm

The choice of method depends on the specific research question, with Western blotting providing isoform information, mass spectrometry offering precise molecular identification, and ELISA enabling high-throughput quantification.

How can CD44 antibodies be engineered for enhanced therapeutic potential?

Researchers have developed sophisticated approaches to enhance the therapeutic efficacy of CD44 antibodies:

• Antibody class switching: Converting from IgG1 to IgG2a subclass to enhance immune effector functions. For example, C44Mab-5 (IgG1) was converted to 5-mG2a (IgG2a) to improve antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) .

• Glycoengineering: Producing defucosylated versions of antibodies (e.g., 5-mG2a-f) using FUT8-deficient ExpiCHO-S cells (BINDS-09). This modification significantly enhances ADCC activity against target cells .

• Validation in preclinical models: Testing modified antibodies in xenograft models. The defucosylated 5-mG2a-f demonstrated significant suppression of xenograft growth of HSC-2 and SAS oral squamous cell carcinoma cell lines compared to control mouse IgG .

These engineering approaches transform research antibodies into potential therapeutic candidates by enhancing their ability to activate immune effector functions against CD44-expressing cancer cells.

What is the significance of intraneuronal Aβ immunoreactivity in Alzheimer's disease research?

When using beta amyloid antibodies like 44-344 for Alzheimer's disease research, it's critical to understand the implications of intraneuronal Aβ immunoreactivity:

• Predictive value: Research using these antibodies has revealed that intraneuronal Aβ immunoreactivity is not a reliable predictor of brain amyloidosis or neurofibrillary degeneration .

• Distribution patterns: The strongest intraneuronal Aβ17-42 immunoreactivity was observed in structures with low susceptibility to fibrillar Aβ deposition, neurofibrillary degeneration, and neuronal loss compared to areas more vulnerable to Alzheimer-type pathology .

• Differential secretase involvement: The prevalence of products of α- and γ-secretases in neurons versus β- and γ-secretases in plaques argues against major contribution of Aβ-immunopositive material detected in neuronal soma to amyloid deposit in plaques .

• N-terminally truncated species: The presence of N-terminally truncated Aβ17-40 and Aβ17-42 in control brains has been confirmed by Western blotting and mass spectrometry, suggesting these species may have distinct roles from full-length Aβ peptides .

Understanding these nuances is essential for correctly interpreting immunohistochemical findings using 44-series antibodies in Alzheimer's disease research.

How do CD44 variant expression patterns correlate with cancer prognosis?

Research utilizing CD44 variant-specific antibodies has revealed important correlations between CD44 variant expression and cancer outcomes:

• Prognostic significance: CD44 overexpression has been found to be predictive of worse disease-free survival and resistance to chemotherapy in various cancer types .

• Cancer stem cell properties: CD44 has been established as a marker of tumor-initiating cells, with specific variants promoting stemness, cancer cell invasion or metastasis, and resistance to chemo- and radiotherapy .

• Variant-specific functions: Different CD44 variants appear to play distinct roles in cancer progression:

  • CD44v4: While specific functions are still being elucidated, the development of C44Mab-108 enables investigation of this variant in oral squamous cell carcinoma and other cancers

  • CD44v6: Associated with invasion and metastasis in several cancer types

  • CD44v9: Often linked to cancer stemness and therapy resistance

• Combinatorial analysis: The comprehensive panel of anti-CD44v mAbs enables researchers to perform detailed analysis of CD44 variant expression patterns in human tumors, potentially identifying clinically relevant subgroups .

These findings highlight the importance of specific detection of CD44 variants in cancer research and potential therapeutic targeting.

What are the common challenges in beta amyloid antibody usage and how can they be addressed?

Researchers working with beta amyloid antibodies like 44-344 and 44-348 often encounter several technical challenges:

• Epitope masking: Amyloid fibrils may mask epitopes, reducing antibody access.

  • Solution: Perform formic acid pretreatment (90% formic acid for 30 minutes) to enhance epitope accessibility .

• Cross-reactivity with APP: Some antibodies may cross-react with amyloid precursor protein (APP).

  • Solution: Use antibodies with confirmed specificity for cleaved Aβ peptides, like 44-344 which specifically recognizes the C-terminus of Aβ42 .

• Distinguishing Aβ isoforms: Differentiating between Aβ40 and Aβ42 can be challenging.

  • Solution: Use C-terminal specific antibodies like 44-344 (for Aβ42) and 44-348 (for Aβ40) that have demonstrated specificity .

• Detection of low abundance species: Some Aβ species may be present at very low concentrations.

  • Solution: Employ immunopurification followed by Western blotting or mass spectrometry for enhanced sensitivity .

• Quantification accuracy: Comparing results across different antibody lots.

  • Solution: Include appropriate positive controls and standards with each experiment and validate new antibody lots against reference standards .

How can researchers optimize CD44 variant antibody specificity in complex tissue samples?

When working with heterogeneous tissue samples containing multiple CD44 variants, researchers can employ several strategies to ensure specificity:

• Sequential immunostaining: Apply multiple CD44 variant antibodies to serial sections to create a comprehensive profile of variant expression .

• Antibody validation controls:

  • Use cell lines with defined CD44 variant expression patterns as positive and negative controls

  • Include isotype control antibodies to identify non-specific binding

  • Employ CD44-knockout samples when available as definitive negative controls

• Epitope mapping: Understanding the precise epitope recognized by each antibody helps predict and explain potential cross-reactivity. For example, C44Mab-5 and C44Mab-46 have epitopes within the constant exon 2- and 5-encoded sequences .

• Complementary detection methods: Confirm immunohistochemistry findings with alternative methods such as RT-PCR for CD44 variant mRNA expression or flow cytometry of dissociated tissue samples .

• Antibody cocktails: For comprehensive CD44 analysis, researchers can use combinations of variant-specific antibodies. The specificity of each antibody in the cocktail should be validated to avoid interference .

What approaches exist for combining multiple CD44 antibodies in comprehensive tumor analysis?

Researchers have developed sophisticated strategies for comprehensive CD44 variant profiling in tumors:

• Multiplexed immunohistochemistry:

  • Apply multiple CD44 variant antibodies labeled with different fluorophores

  • Use spectral unmixing to distinguish signals from different antibodies

  • This approach reveals the heterogeneity of CD44 variant expression within tumors

• Coordinated application of the complete anti-CD44 antibody panel:

  • C44Mab-5 (pan-CD44) provides baseline CD44 expression

  • Variant-specific antibodies (C44Mab-6, C44Mab-108, C44Mab-3, C44Mab-9, C44Mab-34, C44Mab-1, C44Mab-18) reveal the specific variant profile

  • This comprehensive approach is essential for thoroughly analyzing human tumors

• Correlation with functional assays:

  • Combine CD44 variant profiling with assays for stemness, invasion, and therapy resistance

  • This integration allows researchers to connect specific variants with functional properties

• Therapeutic antibody combinations:

  • Engineered antibodies like 5-mG2a-f (defucosylated anti-CD44) can be combined with other therapeutic antibodies

  • Such combinations may enhance anti-tumor efficacy through complementary mechanisms

What are the latest advancements in CD44 antibody development?

Recent innovations in CD44 antibody technology include:

• Novel hybridoma generation methods: The Cell-Based Immunization and Screening (CBIS) method has been used to develop antibodies like C44Mab-5, enhancing the efficiency of antibody discovery .

• Development of variant-specific antibodies: Researchers have successfully created antibodies that specifically recognize individual CD44 variants, such as C44Mab-108 for CD44v4 and C44Mab-34 for CD44v7/8 .

• Antibody engineering for enhanced effector functions:

  • Subclass switching (IgG1 to IgG2a)

  • Glycoengineering to produce defucosylated antibodies

  • These modifications significantly improve ADCC and CDC activities against cancer cells

• Validation in multiple applications: Modern CD44 antibodies are validated across numerous platforms including flow cytometry, Western blotting, immunohistochemistry (including FFPE tissues), and in vivo models .

• Therapeutic development: Anti-CD44 antibodies like 5-mG2a-f have demonstrated significant anti-tumor activity in xenograft models, highlighting their potential as therapeutic agents .

These advancements provide researchers with increasingly sophisticated tools for investigating CD44 biology and developing targeted therapies against CD44-expressing cancers.

What experimental data supports the specificity of 44-344 for Aβ42?

The beta Amyloid (1-42) Polyclonal Antibody (44-344) has been extensively characterized:

This data confirms the high specificity of 44-344 for Aβ42, making it a valuable tool for detecting this specific amyloid beta isoform in research settings .

What is the binding affinity of C44Mab-108 and how was it determined?

The binding affinity of C44Mab-108 (anti-CD44v4) has been precisely quantified:

This moderate binding affinity is sufficient for most research applications including flow cytometry, Western blotting, and immunohistochemistry of FFPE tissues .

What is the reactivity profile of intraneuronal Aβ detected by 44-series antibodies?

Studies using beta amyloid antibodies have characterized intraneuronal Aβ immunoreactivity patterns:

The detection of N-terminally truncated Aβ species (Aβ17-40 and Aβ17-42) in control brains suggests that intraneuronal Aβ immunoreactivity is not a reliable predictor of Alzheimer's pathology .

How are CD44 antibodies being developed for therapeutic applications?

Current research is advancing CD44 antibodies toward therapeutic applications through several approaches:

• Enhanced effector functions: Researchers have successfully converted the mouse IgG1 antibody C44Mab-5 into an IgG2a subclass (5-mG2a) and further produced a defucosylated version (5-mG2a-f) using FUT8-deficient ExpiCHO-S cells. These modifications resulted in demonstrable ADCC and CDC activities against oral squamous cell carcinoma cell lines .

• In vivo efficacy: The defucosylated 5-mG2a-f antibody significantly suppressed the growth of HSC-2 and SAS xenografts compared to control mouse IgG, validating its potential therapeutic efficacy .

• Variant-specific targeting: The development of antibodies against specific CD44 variants (v3, v4, v5, v6, v7/8, v9, v10) enables precise targeting of cancer subtypes that overexpress particular variants, potentially reducing off-target effects .

• Combinatorial strategies: Research suggests that combining multiple anti-CD44 variant antibodies or combining them with other therapeutic modalities could enhance anti-cancer efficacy .

These advances demonstrate the potential of CD44 antibodies as targeted therapeutics for cancers overexpressing CD44 variants.

What future applications exist for Aβ antibodies in neurodegenerative disease research?

Beta amyloid antibodies like 44-344 and 44-348 are poised for several emerging applications:

• Early disease biomarkers: Improved understanding of intraneuronal Aβ species may help identify early biomarkers of neurodegenerative processes before plaque formation .

• Differentiating Aβ species: The ability to distinguish between different Aβ isoforms (Aβ40 vs. Aβ42) and truncated forms (e.g., Aβ17-40, Aβ17-42) enables more nuanced investigation of their distinct roles in disease pathogenesis .

• Therapeutic antibody development: Insights gained from research antibodies like 44-344 inform the development of therapeutic antibodies targeting specific Aβ species or conformations.

• Combined biomarker approaches: Integrating Aβ antibody-based detection with other biomarkers (tau, inflammatory markers) could improve diagnostic accuracy and disease monitoring.

• Non-Alzheimer's applications: These antibodies have potential utility in investigating Aβ's role in other conditions such as cerebral amyloid angiopathy, Down syndrome, and traumatic brain injury.

Understanding the complex relationship between different Aβ species and their cellular localization continues to be crucial for developing effective therapeutic strategies for neurodegenerative diseases.